Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups

• Egile Nagusiak: Simeon Rüdesheim (Egilea), Dominik Selzer (Egilea), Uwe Fuhr (Egilea), Matthias Schwab (Egilea), Thorsten Lehr (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2022-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract This study provides a whole‐body physiologically‐based pharmacokinetic (PBPK) model of dextromethorphan and its metabolites dextrorphan and dextrorphan O‐glucuronide for predicting the effects of cytochrome P450 2D6 (CYP2D6) drug‐gene interactions (DGIs) on dextromethorphan pharmacokinetics...